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Summary
 
Nonpeptidic compounds stimulate human T cells bearing the TCR-
 
gd
 
 in the absence of major
histocompatibility complex restriction. We report that one of these ligands, 2,3-diphospho-
glyceric acid (DPG), which induces expansion of V
 
g
 
9/V
 
d
 
 T cells ex vivo, antagonizes the same
cell population after repetitive activation. Stimulation with DPG results in partial early protein
tyrosine phosphorylation and a prolonged, but reversible, state of unresponsiveness to agonist
ligands in V
 
g
 
9/V
 
d
 
2, but not in other T cells. These findings show that TCR antagonism is a
general phenomenon of T cells. However, in contrast to the clonal specificity of altered pep-
tides antagonizing 
 
ab
 
 T cells, all the tested V
 
g
 
9/V
 
d
 
2 polyclonal cell lines and clones become
unresponsive, a fact that may be relevant for the regulation of their response in vivo.
 
H
 
uman 
 
gd
 
 cells bearing the V
 
g
 
9 (TCRGV2S1)/
V
 
d
 
2(TCRDV102S1) TCR react to a variety of phos-
phorylated nonpeptidic ligands (1–4), some of which are
natural metabolites (5). The TCR participates in the stimu-
lation of the cells by such ligands as evidenced by reconsti-
tution of reactivity when V
 
g
 
9 and V
 
d
 
2, but not other V
 
g
 
or V
 
d
 
 genes, are co-transfected into a nonresponder T cell
line (6). 
 
gd
 
 T cell recognition of phosphorylated nonpep-
tidic ligands has two remarkable characteristics (5): (
 
a
 
) it is
highly specific, since minor modifications in the structure
of the ligand abolish recognition, and (
 
b
 
) all V
 
g
 
9/V
 
d
 
2 cells
ex vivo and clones show the same specificity since they are
broadly cross-reactive against different metabolites, and all
ligands display the same relative potency on all tested T cell
clones and polyclonal lines. Without exception, we observe
that in vitro cultivated 
 
gd
 
 T cells progressively lose their
capacity to proliferate in response to the weaker ligands
first, and to the stronger ones later on, while maintaining
their ability to react to mitogens and to express similar lev-
els of TCR (monitored by flow cytometry analysis using
antibodies against CD3
 
e
 
, C
 
d
 
, V
 
g
 
9, and V
 
d
 
2, data not
shown).  This consistent loss of proliferative capacity does
not necessarily imply a loss of reactivity, but might reflect a
change in biological responsiveness. We have investigated
the possibility that a ligand which functions as an agonist
during the beginning of the immune response, may act as
an antagonist on the same cells in later phases.
 
Materials and Methods
 
Cells and Cell Culture.
 
Cells were cultured in RPMI 1640
medium supplemented with 2 mM glutamax I, 100 
 
m
 
g/ml kana-
mycin, MEM nonessential amino acids, 1 mM Na pyruvate (all
from GIBCO BRL, Basel, Switzerland), human serum 5% (Bluts-
pendezentrum, Bern, Switzerland), and 100 U of recombinant hu-
man IL-2 (IL-2), unless mentioned as IL-2–free medium. The
V
 
g
 
9/V
 
d
 
2 cell lines were raised by culturing 10
 
6
 
 freshly isolated
human PBMC with a single dose of the indicated ligand (50 
 
m
 
g/
ml 
 
Mycobacterium tuberculosis
 
 [
 
M. tub.
 
]
 
1
 
 (Difco Laboratories, Detroit,
MI), 10 
 
m
 
l/ml protein-free extract from 
 
M. tub
 
. (PFE), 1 mM
xylose-1-phosphate (X1P), 1 mM ribose-1-phosphate (R1P), or 100
 
m
 
M isopentenylpyrophosphate (IPP; Sigma, Buchs, Switzerland).
After 72 h, 50 U of IL-2 was added to the cultures. T cell clones
were established as reported (7) by limiting dilution using PHA
(1 
 
m
 
g/ml; Wellcome, Dartford, UK), IL-2 (100 U/ml), and irradi-
ated PBMC (5 
 
3
 
 10
 
5
 
/ml). T cell clones were restimulated period-
ically following the same protocol (7).
 
Flow Cytometry.
 
V
 
g
 
9/V
 
d
 
2 cells were incubated in the pres-
ence of indicated stimuli for 3 h, and then maintained on ice dur-
ing staining with mAbs against CD3
 
e
 
 (TR66) or C
 
d
 
 (
 
d
 
1), and an-
alyzed using a FACScan
 
Ò
 
 flow cytometer. Data analysis was
performed using CELLQuest (Becton Dickinson, San Jose, CA).
 
Proliferation Assay.
 
Proliferation assays were performed in IL-2–
free medium using 10
 
5
 
 responder cells/well and 30 Gy-irradiated
 
1
 
Abbreviations used in this paper:
 
 DPG, 2,3-diphosphoglyceric acid; E/T,
effector/target; IPP, isopentenylpyrophosphate; MFI, median fluores-
cence intensity; 
 
M. tub.
 
, 
 
Mycobacterium tuberculosis
 
.
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PBMC (10
 
5
 
/well) as APC. After 48 h, 1 
 
m
 
Ci/well of [
 
3
 
H]thymi-
dine (TRK120; Amersham Intl., Little Chalfont, England), was
added and the cultures were harvested after an additional 18 h.
Results are shown as mean cpm 
 
6
 
 SD.
 
TNF Release Assay.
 
10
 
4
 
 responder cells were incubated with
the indicated ligand, and culture supernatants were collected after
6 h. 15 
 
3
 
 10
 
3
 
 WEHI 164.13 cells were incubated for 18 h with ap-
propriately diluted supernatant in the presence of actinomycin D
(2.5 
 
m
 
g/ml). After a further 4 h incubation with 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 500 
 
m
 
g/ml),
the cells were lysed and the reduced MTT dissolved by adding
an equal volume of HCl 0.04 N in isopropanol. OD
 
560
 
–OD
 
650
 
was determined using a THERMOmax Microplate Reader with
SOFTmax (Molecular Devices Corp., Menlo Park, CA), and the
released TNF calculated by comparison with the OD in the linear
range of a standard curve simultaneously acquired with recombi-
nant human TNF. Results are shown as mean pg/ml 
 
6
 
 SD.
 
Cytotoxicity Assays.
 
In brief, PHA-stimulated T cell blasts
were labeled with 100 
 
m
 
Ci
 
51
 
Cr (Amersham Intl.) and 5,000 cells/
well were incubated in round-bottom wells with V
 
g
 
9/V
 
d
 
2 cells at
the indicated effector/target (E/T) ratios. After 6 h, the amount
of 
 
51
 
Cr released into the supernatant was measured as cpm and
expressed as percent of specific 
 
51
 
Cr release: (effector induced cpm 
 
2
 
spontaneous cpm / maximum cpm 
 
2
 
 spontaneous cpm) 
 
3
 
 100.
Maximum cpm were obtained by target cell lysis with 1 M HCl.
 
Analysis of Protein Tyrosine Phosphorylation.
 
Immunoblot anal-
ysis for protein tyrosine phosphorylation was performed with to-
tal cell lysates. Briefly, T cells (7.5 
 
3
 
 10
 
5
 
 cell equivalents/lane)
were lysed with 100 
 
m
 
l/10
 
6
 
 cells of lysis buffer containing 25 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP40, inhibitors of pro-
teases (1 mM PMSF, 4 
 
m
 
g/ml leupeptin, 4 
 
m
 
g/ml aprotinin), and
inhibitors of phosphates (10 mM EDTA, 1 mM sodium ortho-
vanadate), for 20 min on ice. After removal of nuclear debris by
centrifugation, the supernatant was electrophoresed on 10% SDS-
PAGE and transferred to nitrocellulose membrane (Hybond-C;
Amersham Intl.). Protein tyrosine phosphorylation was detected
using the 4G10 mAb (Upstate Biotechnology Inc., Lake Placid,
NY). The same results were obtained using another phospho-
tyrosine specific mAb (PTyr1; a gift from V. Horejsi). Blots were
developed using horseradish peroxidase–conjugated second anti-
body (sheep anti–mouse Ig; Amersham Intl.) and enhanced chemi-
luminescence (ECL system; Amersham Intl.).
 
Results and Discussion
 
A ligand and intermediate potency, 2,3-diphosphoglyceric
acid (DPG), was compared with a ligand with high po-
tency, IPP (4, 5). Fresh 
 
gd
 
 T cells fully respond to both
compounds. However, 
 
gd
 
 T cells in culture gradually lose
their proliferative response to DPG without a change in
their capacity to proliferate in response to IPP.
Throughout this study we have sued V
 
g
 
9/V
 
d
 
2 T cells
which proliferate to IPP, but no longer to DPG. Both
DPG and IPP induce downmodulation of the TCR 
 
gd
 
 on
these cells (Fig. 1), confirming that activation by DPG and
IPP involves TCR stimulation (8). DPG induces TCR
downmodulation without cell proliferation, we investi-
gated whether it might behave as a partial agonist or as an
antagonist (9, 10). DPG induces neither release of IFN
 
g
 
and TNF, nor transcription of IL-1, IL-2, IL-3, IL-4, IL-5,
GM-CSF, IFN-
 
g
 
, and TNF-
 
a
 
 genes in V
 
g
 
9/V
 
d
 
2 cells (as-
sessed by reverse transcriptase-PCR, data not shown), nor
killing of target cells by cytotoxic V
 
g
 
9/V
 
d
 
2 clones (data
not shown), which are all effects detected after stimulation
with IPP. Therefore, it is unlikely that DPG is a partial ag-
onist. In another series of experiments, 
 
gd
 
 T cells were cul-
tured in the presence of both ligands simultaneously (Fig.
2). Although DPG no longer displays its agonistic proper-
ties on cultured 
 
gd
 
 T cells, it nevertheless has a clear dose-
dependent effect whereby it inhibits IPP-induced activa-
tion in a noncompetitive manner. DPG lowers the efficacy
(maximal response) of IPP, but does not alter the potency
of IPP (dose for 50% of maximal effect). These results indi-
cate that DPG does not displace IPP from its binding site,
but that it may act as a TCR antagonist.
To investigate whether stimulation by DPG could result
in a state of altered responsiveness, V
 
g
 
9/V
 
d
 
2 T cells were
preincubated with DPG, and then washed and challenged
with IPP. Preincubation with DPG blocks the subsequent
ability of IPP to stimulate TNF release and cell prolifera-
tion (Fig. 3) indicating that DPG induces a state of unre-
sponsiveness which persists after removal of the ligand. This
prolonged unresponsiveness is not due to inadequate wash-
out of the antagonist, since control cells are fully reactive in
the presence of equal numbers of DPG-preincubated cells
(data not shown). Incubation with DPG for only 5 min is
sufficient to block IPP-mediated TNF release (Fig. 3 
 
A
 
).
The rapidity with which DPG exerts its inhibitory effect
is consistent with observations that phosphorylated non-
peptidic ligands induce Ca
 
2
 
1
 
 fluxes in V
 
g
 
9/V
 
d
 
2 T cells
within 2 min (11, 12). The IPP-unresponsiveness induced
by DPG is not a consequence of cell death since the num-
ber of viable cells recovered is the same (70–100%) as
controls, and the cells remain responsive to low doses (20
U/ml) of IL-2 (Fig. 3 
 
B
 
). Furthermore, once a state of un-
responsiveness is induced, it lasts for 1–5 d (using different
Figure 1. DPG induces downmodulation of the TCR gd. Overlaid
histograms of immunostaining of d1 mAB on Vg9/Vd2 clone Z1P 101
simulated with medium (—, median fluorescence intensity [MFI] 138,
100%), 1 mM DPG (—, MFI 99, 71%), IPP 100 mM (---, MFI 100,
72%), and PHA 1 mg/ml (…, MFI 55, 40%). Similar results were ob-
tained with several different Vg9/Vd2 cell lines and clones, but not with
control clones bearing other types of TCR.93 Bürk et al.
cell lines and clones), after which the cells regain their
ability to respond to the agonist (Fig. 3 B). The induction
of unresponsiveness by DPG differs from the induction of
T cell refractoriness by repetitive stimulation with agonist
ligands. Indeed, (a) gd cells stimulated by DPG become
unresponsive without induction of effector functions, and
(b) the induction of unresponsiveness by DPG has a domi-
nant effect even over simultaneous stimulation by IPP (Fig. 2).
Proliferation and lymphokine release both require nu-
clear gene activation. To study whether effects induced by
earlier signaling events are altered by DPG, we performed
cytotoxicity assays. IPP stimulates cytotoxic Vg9/Vd2 cells
to kill target cells at low E/T ratios; however, IPP does not
trigger killing by the same cells preincubated with DPG
(Fig. 4). These results suggest that in unresponsive cells, not
only late events, but also earlier signaling events leading to
cytotoxic activity are affected.
To determine which signal transduction pathways might
be affected, we applied various procedures described to
prevent anergy induction or restore responsiveness. While
cyclosporin A completely prevents anergy with ab T cells
(13, 14), it has only a partial effect on gd T cells (data not
shown). This suggests that both the late signals blocked by
cyclosporin A, as well as other signals, participate in estab-
lishing unresponsiveness. IPP-unresponsive cells could be
stimulated by PHA or a combination of PMA and Ca21
ionophore (Fig. 5). Importantly, reactivity to IPP could be
restored by PMA, which was not stimulatory by itself.
Thus, IPP can apparently still trigger unresponsive cells with
a signal that is mimicked by Ca21 ionophore. In addition,
the ability of PMA to overcome unresponsiveness indicates
that the blockade of signaling in unresponsive cells most
likely occurs between the TCR and P21ras. Blockade of
proximal signaling has been recently shown in two ab
T cell anergy models (15, 16).
Alterations of the TCR proximal signals have been pre-
viously described for modified peptide ligands which in-
duce unresponsiveness in TCR ab clones (17, 18). To in-
vestigate whether early signals are also altered in gd T cells,
the IPP- and DPG-induced protein tyrosine phosphoryla-
tion patterns were compared. A similar spectrum of phos-
Figure 2. DPG reduces the efficacy, but not the potency, of IPP. Pro-
liferation (A) and TNF release (B) of the gd T cell line PG96 coincubated
with different concentrations of IPP and DPG (1 mM, j; 500 mM, d;
250 mM, m; 125 mM, r), or medium (s). Comparable dose-response
curves were obtained in four independent experiments.
Figure 3. DPG rapidly induces a prolonged, but reversible, state of un-
responsiveness to IPP. (A) The Vg9/Vd2 cell line BCI 31 was incubated
with DPG for the time indicated on the x-axis. After extensive washing,
the TNF release stimulated by 50 mM IPP (j) or 1 mg/ml PHA (d) was
measured. (B) Vg9/Vd2 clone BCI 49 (2 3 106 cells/ml) was incubated
in IL-2–free medium with 1 mM DPG overnight and washed exten-
sively. The cells were then rested in medium for the time indicated on the
x-axis. Proliferative responses to medium (r), 100 mM IPP (j), or 20
U/ml IL-2, (s) are shown. h indicates control proliferation to IPP (100
mM) of the same cells not preincubated with DPG. Results obtained in
four independent experiments using different Vg9/Vd2 clones showed
recovery of responsiveness after 1 to 5 d. Preincubation with DPG did
not affect the responsiveness of CD41 TCR ab cells to their specific pep-
tide (data not shown).94 Nonpeptidic Antagonist for the Whole Human Vg9/Vd2 T Cell Population
phorylated proteins was detected (Fig. 6). However, the
overall level of phosphorylation induced by DPG was
quantitatively less than that induced by IPP.
The presented data show that TCR gd antagonism has
several characteristics in common with TCR ab antago-
nism induced by altered peptide ligands (9, 19, 20). How-
ever, there are also important differences. In Vg9/Vd2 T
cells, the antagonistic effects of DPG occur only after cell
activation and extensive proliferation. Since the effects of
DPG are observed without changes in its structure, the
change in response must be due to a change occurring in
the T cells. Cultured gd T cells, on which DPG has lost its
agonistic effects, express normal levels of TCR, which can
transduce a full signal after stimulation with IPP. There-
fore, it is likely that molecules other than the TCR are in-
volved in the altered responsiveness to DPG. In our case,
modified expression of costimulatory molecules seems un-
likely, because cells which have lost the capacity to prolif-
erate with DPG still proliferate with IPP, implying ade-
quate costimulation. Yet, triggering the TCR with various
stimuli in the absence of costimulation always leads to ab
T cell anergy (21, 22). The finding that cytotoxicity, which
is not so dependent on costimulation (23), is lost in unre-
sponsive cells also supports this conclusion.
The hypophosphorylation observed after DPG stimula-
tion indicates that the signal transduction cascade is af-
fected, and this might be due to loss of molecules important
in the signaling pathway. Interestingly, the potency of DPG
as agonist is the same as its potency as antagonist (ED50 250
mM), thus implying that DPG interacts with its receptor
with the same affinity on both fresh and expanded gd cells
and that the nonproliferating gd cells have not modified
the receptor for DPG. We hypothesize that responsiveness
of Vg9/Vd2 cells is modulated by the expression levels of a
(unknown) molecule with a coreceptor-like function simi-
lar to that described for CD4 and CD8 coreceptors on ab
cells (24–29). Based on the presented data, our hypothesis
predicts that stimulation of gd T cells with strong ligands
(e.g., IPP) is largely independent of coreceptor density,
while stimulation with weak ligands (e.g., DPG) would re-
quire a high density. If the coreceptor density is reduced,
weak ligands switch their properties from being agonists to
antagonists. A progressive loss of the coreceptor might al-
low a given ligand to function as a full agonist in the early
phase of the immune response, and subsequently acquire an-
tagonistic properties and regulatory functions.
A second important difference is that while most of the
TCR ab antagonists are highly T cell clone specific, DPG
is broadly active on human Vg9/Vd2 T cells. When many
different gd T cell lines and clones from various donors are
tested, all the Vg9/Vd2 cells become unresponsive, irre-
spective of the ligand used to expand the original cell lines
(Table 1). This is observed with assays detecting either pro-
liferation or TNF release.
Figure 4. Early signaling events, necessary for cytolytic function, are al-
tered in cells made unresponsive by DPG. The figure shows results of kill-
ing of PHA-blasts by Vg9/Vd2 clone RNM.t.73 preincubated overnight
with medium (solid symbols) or DPG 1 mM (open symbols) in the presence
(squares) or absence (circles) of 100 mM IPP, at the indicated E/T ratios.
Figure 5. Unresponsiveness induced by DPG is the consequence of
the alteration of TCR proximal signals. Vg9/Vd2 clone BCI 49 (106 cells/
ml) was incubated overnight in IL-2–free medium with 1 mM DPG
and washed extensively. Proliferative responses to medium, 100 mM IPP,
1 mg/ml PHA, 500 ng/ml Ca21 Ionophore A23187 (Iono) 50 ng/ml PMA,
or the indicated combinations were measured.
Figure 6. Upon DPG treat-
ment, tyrosine phosphorylation
of TCR-associated proteins is
reduced when compared to IPP
stimulation. Vg9/Vd2 T cells
were incubated for 10 min with
either medium (C), 100 mM
IPP, 1 mM DPG, or 1 mg/ml
PHA. Protein tyrosine phosphor-
ylation is visualized by immuno-
blotting of total cell lysates. Sim-
ilar results were obtained in four
independent experiments using
Vg9/Vd2 cell lines and clones.
IPP and DPG did not induce any
protein tyrosine phosphoryla-
tion in TCR ab cells (data not
shown).95 Bürk et al.
The induction of a state of unresponsiveness in a whole
lymphocyte subpopulation may have important consequences
for the immune response of gd T cells. It has been proposed
that gd T cells provide an efficient first line of defense against
infectious agents (30, 31). This property may derive from
their ability to broadly cross-react with many ligands (5)
and with diverse microorganisms (7, 32–36). However, this
promiscuous ligand recognition might lead to an uncon-
trolled expansion of Vg9/Vd2 T cells with harmful effects
for the organism. The presently described regulatory mech-
anism could control the whole Vg9/Vd2 T cell population
in a late phase of the immune response. A paradigmatic ex-
ample might be malaria infection where either plasmodium
ligands or DPG, which is present inside red blood cells at a
physiological concentration of z5 mM, are released after
massive erythrocyte rupture. In patients with acute malaria,
a synchronized erythrocyte rupture is followed by hyperac-
tivation of the Vg9/Vd2 population (37, 38) and by a mas-
sive release of TNF resulting in a severe clinical picture
(39). The recurrent release of nonpeptidic ligands from
ruptured red blood cells and the successive activation and
expansion of gd T cells could change gd T cell reactivity,
and thereby result in a beneficial unresponsiveness. Indeed,
patients with the chronic form of malaria experience nei-
ther Vg9/Vd2 cell expansion nor raised TNF serum levels
and have an asymptomatic clinical course (38).
In summary, the presented data provide a rationale for
manipulating the reactivity of the whole Vg9/Vd2 T cell
population and offer a new model with which to assess
whether TCR antagonism is an important principle of T cell
regulation.
Table 1. Unresponsiveness of Vg9/Vd2 Polyclonal Lines and Clones After Overnight Incubation with DPG
Response to: Medium IPP IL-2 PHA
Preincubation with DPG: No Yes No Yes No Yes No Yes
Donor Raised against Proliferation
cpm
OP M. tub. 2,039 1,280 15,175 1,160 11,785 10,584 13,961 15,927
VJ M. tub. 6,353 3,366 12,061 3,087 12,827 13,003 10,488 14,474
GDL M. tub. 1,320 5,075 27,385 6,899 31,537 36,617 16,890 23,029
GDL R1P 628 1,360 19,198 1,870 12,086 16,345 15,123 17,415
GDL X1P 7,324 5,757 12,104 6,171 17,094 16,486 23,042 22,941
GDL PFE 10,607 8,178 70,393 7,326 ND ND ND ND
BCI 49* IPP 381 706 37,324 1,767 44,938 50,429 19,102 19,514
BCI 5* IPP 411 323 24,857 1,080 ND ND 6,350 8,388
TNF release
pg/ml
GDL M. tub. ND 744 14,746 2,295 ND ND ND ND
GDL IPP ND 101 5,147 956 ND ND 4,658 3,102
BCI 13* IPP ND 475 7,585 1,736 ND ND ND ND
G2C25* PHA ,15 ,15 2,369 155 ND ND ND 1,649
*Vg9/Vd2 T cell clone. PFE, protein-free extract from M. tub.; R1P, ribose-1-phosphate; X1P, xylose-1-phosphate. Each line or clone was tested
two to four times.
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